Enzon Pharmaceuticals Inc (ENZN) fair value: what the stock is really worth
As of Jul 24, 2026: fair value of Enzon Pharmaceuticals Inc $3.25, price $4.15, upside -21.7%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Enzon Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $3.50 – $73.90 · fair‑value band $1.66 – $4.83 · the $4.15 price screens above the $3.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Enzon Pharmaceuticals in your weekly email
Every Wednesday you see whether Enzon Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Viskase Companies, Inc., together with its subsidiaries, produces and sells non-edible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products and services in North America, South America, Europe, Asia, and internationally.
Show more
Viskase Companies, Inc., together with its subsidiaries, produces and sells non-edible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products and services in North America, South America, Europe, Asia, and internationally. The company offers NOJAX cellulose casings for use in the automated production of hot dogs, dry mini salamis, and cooked and coarse ground sausages; and large cellulose casings to give cylindrical or oval shape to the processed meats that are used in bologna, mortadella, deli ham, bierwurst, and dry sausages. It also provides VISDRY casings for dried or smoked sausages; VISFLEX casings for cheese and processed meat applications; VISMAX casings for molded, and formed processed meat and poultry applications; VISLON for meat, poultry, and cheese applications; VISMOKE casings for cooked and smoked meat products, semi-dry sausages, and spreadable dry sausages; VISCOAT casings for a range of applications, including turkey, ham, and roast beef products; and POLYJAX casings for the production of hot dog, sausage, chorizo products, and meat snack sticks. In addition, the company provides fibrous casings for use in a range of applications, including pepperoni, salami, boneless hams, luncheon meats, and other deli-style processed meats, as well as for processed and smoked cheeses; color transfer casings for a range of natural and synthetic shades; flavor transfer casings for taste profiles; smoke transfer casings for processed meat or cheese products; and spice transfer casings for processing facility. Additionally, it offers textile spice transfer casings for transfer of the spice to the food; Ve-Net products; and MEMBRA-CEL, a dialysis membranes made from regenerated cellulose. The company was founded in 1925 and is based in Lombard, Illinois. Viskase Companies, Inc. is a subsidiary of Icahn Enterprises L.P.
Stock analysis
Enzon Pharmaceuticals Inc (ENZN) currently trades at $4.15, while our model-based Fair Value estimate is $3.25, 21.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $14.78 per share, and 1 of the 3 models we run sit above the $4.15 price.
Bear case: the Dividend Discount group reads lowest at $2.92, and 2 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $1.66 (bear) to $4.83 (bull), the price of $4.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Enzon Pharmaceuticals Inc reported revenue of $364M in FY2025 versus $701K in FY2021, a compound +377.5%/yr. Reported net income was −$65.5M in FY2025.
Key figures
Market cap $36.4M · P/S ratio 0.10 · EPS (TTM) $−9.98 · Dividend yield 3.5% · Net margin −18.0% · Return on equity −32.3% · Return on assets (EBIT) 22.7% · Operating margin −4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −16% fair-value upside, at −22%, ENZN screens richer than that median.
Fair Value models
Bear $1.66Fair Value $3.25Bull $4.83
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−9.8%
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
’12
’13
’14
’15
’16
’17
’18
’19
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,509.6% (2020) → −4.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Enzon Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaging & Containers · 262 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−21.7% · Below median
Profitability
Return on assets−3.6% · Bottom 25%
Net margin (TTM)−16.4% · Bottom 25%
Operating margin (TTM)−4.8% · Bottom 25%
Growth and dividend
Revenue growth−8.1% · Bottom 25%
Dividend yield (TTM)3.5% · Above median
Balance sheet
Debt / equity0.89× · Highest 25%
Valuation Multiplesvs Packaging & Containers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Enzon Pharmaceuticals Inc (ENZN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.25 versus the last price from Jul 24, 2026 of $4.15, about −22% upside (overvalued).
What is the fair value of ENZN?
Our model-based fair value for Enzon Pharmaceuticals Inc is $3.25 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 24, 2026): $4.15.
What is the quality score of ENZN?
Enzon Pharmaceuticals Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enzon Pharmaceuticals Inc (ENZN)?
Our model-based price target is the fair value of $3.25 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario $1.66, optimistic scenario $4.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Enzon Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $3.25, about −22% upside versus the last price from Jul 24, 2026 of $4.15 (overvalued). Cautious scenario $1.66, optimistic scenario $4.83. The calculation is refreshed regularly with new filings.
What is the revenue of Enzon Pharmaceuticals Inc (ENZN)?
Enzon Pharmaceuticals Inc reported trailing-twelve-month revenue of about $357M (latest available figure, as of Sep 24, 2026).
Does Enzon Pharmaceuticals Inc pay a dividend?
Enzon Pharmaceuticals Inc currently shows a dividend yield of about 3.51% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Enzon Pharmaceuticals Inc (ENZN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enzon Pharmaceuticals Inc it is $3.25 per share (as of Sep 24, 2026), against a price of $4.15. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Enzon Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ENZN trades above its calculated fair value: price $4.15, fair value $3.25, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENZN?
No. The price is what the market pays today ($4.15); the fair value is what the company's own numbers justify ($3.25). For Enzon Pharmaceuticals Inc the two are $0.9000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enzon Pharmaceuticals Inc worth?
The market values Enzon Pharmaceuticals Inc at about $36.4M (market capitalisation, as of Sep 24, 2026). Per share that is $4.15; our models calculate a fair value of $3.25 per share.
What do the bullish and bearish scenarios say about ENZN?
Our models span a range for Enzon Pharmaceuticals Inc: cautious scenario $1.66, base $3.25, optimistic $4.83 per share (as of Sep 24, 2026, price $4.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enzon Pharmaceuticals Inc (ENZN)?
Balance-sheet figures for Enzon Pharmaceuticals Inc (as of Sep 24, 2026): return on equity −32.3%, debt of 0.89 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is ENZN from its 52-week high?
Enzon Pharmaceuticals Inc trades at $4.15, about 56% below its 52-week high of $9.47 and 19% above the low of $3.50 (as of Jul 24, 2026). Distance from the high says nothing about value: that is what the fair value of $3.25 is for.
Which stocks are comparable to Enzon Pharmaceuticals Inc?
From the same area (Consumer Cyclical) we also value Smurfit Westrock Plc,, Packaging Corporation, International Paper Company, Ball Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enzon Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $4.15, calculated fair value $3.25 (−22%), Quality Score 23/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENZN calculated?
We run Enzon Pharmaceuticals Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Enzon Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enzon Pharmaceuticals Inc (ENZN)?
The latest price we hold is from Jul 24, 2026 and stands at $4.15. Our model-based fair value is $3.25, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enzon Pharmaceuticals Inc right now?
Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($1.66 to $4.83). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Enzon Pharmaceuticals Inc
How large is the market capitalisation of Enzon Pharmaceuticals Inc (ENZN)?
The market capitalisation of Enzon Pharmaceuticals Inc is $36.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enzon Pharmaceuticals Inc (ENZN)?
The price-to-sales ratio of Enzon Pharmaceuticals Inc is 0.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enzon Pharmaceuticals Inc (ENZN)?
Earnings per share at Enzon Pharmaceuticals Inc are $−9.98. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Enzon Pharmaceuticals Inc (ENZN)?
The dividend yield of Enzon Pharmaceuticals Inc is 3.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Enzon Pharmaceuticals Inc (ENZN)?
The net margin of Enzon Pharmaceuticals Inc is −18.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Enzon Pharmaceuticals Inc (ENZN)?
The return on equity (ROE) of Enzon Pharmaceuticals Inc is −32.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enzon Pharmaceuticals Inc (ENZN)?
On an EBIT basis the return on assets of Enzon Pharmaceuticals Inc is 22.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Enzon Pharmaceuticals Inc (ENZN)?
The operating margin of Enzon Pharmaceuticals Inc is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Enzon Pharmaceuticals Inc (ENZN)?
Revenue at Enzon Pharmaceuticals Inc is growing −8.1% versus a year earlier (3y avg +2,311%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Enzon Pharmaceuticals Inc (ENZN)?
Earnings per share at Enzon Pharmaceuticals Inc are growing −70.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Enzon Pharmaceuticals Inc (ENZN) generate?
The free cash flow of Enzon Pharmaceuticals Inc is −$22.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Enzon Pharmaceuticals Inc in the live analysis
One click puts Enzon Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026